# Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

> **NCT00193570** · PHASE1 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 20 (—)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00193570
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2004-08
- **Final completion:** 2009-01
- **Target enrollment:** 20 (—)
- **Last updated:** 2009-01-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193570, "Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00193570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*